{
  "ticker": "IRX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967360",
  "id": "02967360",
  "pages": 9,
  "price_sensitive": false,
  "date": "20250708",
  "time": "1435",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06llq02r2g29fp.pdf",
  "summary": "### Key Material Information:\n\n1. **Director Securities Issuance**  \n   - **Performance Rights Issued (in lieu of fees)**:  \n     - Total: 2,324,926 Performance Rights  \n     - Price: $0.040 per right (based on 30-day VWAP)  \n       - Sean Williams: 1,074,866 rights ($42,732)  \n       - Dr Ron Wise: 746,736 rights ($29,687)  \n       - Anthony Fitzgerald: 503,324 rights ($20,010)  \n\n   - **Unlisted Options Issued**:  \n     - Total: 1,000,000 options (3-year term)  \n       - Dr Ron Wise: 500,000 options  \n       - Anthony Fitzgerald: 500,000 options  \n\n2. **Funding Facility**:  \n   - Up to $38.5m secured for clinical development of IRX-211 (Breakthrough Cancer Pain) and IRX-616a (Panic Disorder).  \n\n3. **Regulatory Pathway**:  \n   - Targeting U.S. FDA approval via the 505(b)(2) pathway for rapid development.  \n\n*No material trading or capital markets actions required (e.g., no equity raise, halt, or cash balance update).*",
  "usage": {
    "prompt_tokens": 3651,
    "completion_tokens": 264,
    "total_tokens": 3915,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-08T05:27:22.098236"
}